An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic mutations

• Register: EUCTR
• Last refreshed on: 30 November 2020
• Main ID: EUCTR2017-002005-36-NL
• Date of registration: 06/09/2017
• Prospective Registration: Yes
• Primary sponsor: Rhythm Pharmaceuticals, Inc.
• Public title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic mutations
• Scientific title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic mutations
• Date of first enrolment: 21/12/2017
• Target sample size: 12
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002005-36
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: yes Other trial design description: The open-label trial includes a double-blind placebo-controlled withdrawal period. If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 1
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

France, Germany, Netherlands, United Kingdom

Contacts

• Name: Fred Fiedorek
• Affiliation: Rhythm Pharmaceuticals, Inc.

• Name: Fred Fiedorek
• Affiliation: Rhythm Pharmaceuticals, Inc.

Key inclusion & exclusion criteria

Inclusion criteria:
1. Bi-allelic, homozygous or compound heterozygous (a
different gene mutation on each allele) genetic status for either the LEPR genes, with the
loss-of-function (LOF) variant for each allele conferring a severe obesity phenotype.
2. Age 12 years and above.
3. If adult age =18 years, obesity with body mass index (BMI)
= 30 kg/m2; if child or adolescent, obesity with weight > 97th percentile for age on growth chart assessment.
4. Study participant and/or parent or guardian can communicate well with the investigator, to understand and comply with the requirements of the study, and can understand and sign the written
informed consent/assent, after being informed about the study.
5. Female participants of child-bearing potential must agree to use contraception as outlined in the protocol. Female participants of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post- menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal lab range),
or failure to have progressed to Tanner Stage V and/or failure to have achieved menarche, do not require contraception during the study.
6. Male participants with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study. Male patients must not donate sperm during and for 90 days following their participation in the study.

Are the trial subjects under 18? yes
Number of subjects for this age range: 1
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 10
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
1. Recent intensive (within 2 months) diet and/or exercise
regimen with or without the use of weight loss agents including herbal medications, that has resulted in weight loss or weight stabilization. Patients may be reconsidered approximately 1 month
after cessation of such intensive regimens.
2. Prior gastric bypass surgery resulting in >10% weight loss durably maintained from the baseline pre-operative weight with no evidence of weight regain. Specifically, patients may be considered if surgery was not successful, or resulted in <10% weight loss compared to pre-operative baseline weight or clear evidence of weight regain after an initial response to bariatric surgery. All patients with a history of bariatric surgery must be discussed with, and receive approval from
Rhythm prior to enrollment.
3. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic and Statistical Manual of Mental Disorders (DSM-III) disorders that the investigator believes will interfere significantly with study compliance.
4. A Patient Health Questionnaire-9 (PHQ-9) score of = 15.
5. Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS). Any lifetime history of a suicide attempt, or any suicidal behavior in the last month.
6. Current, severe stable restrictive or obstructive lung disease due to extreme obesity, evidence of significant heart failure (NYHA Class 3 or greater), or oncologic disease, if these were severe enough to interfere with the study and/or would confound the results. Any such patients should be discussed with the sponsor prior to inclusion.
7. History of significant liver disease or liver injury, or current liver assessment for a cause of abnormal liver tests [as indicated by abnormal liver function tests, alanine transaminase (ALT),
aspartate transaminase (AST), alkaline phosphatase, or serum bilirubin (> 2.0 x upper limit of normal (ULN) for any of these tests)] for an etiology other than non-alcoholic fatty liver disease
(NAFLD). Thus, any underlying etiology besides NAFLD, including diagnosed non-alcoholic steatohepatitis (NASH), other causes of hepatitis, or history of hepatic cirrhosis will be exclusionary, but the presence of NAFLD would not be exclusionary.
8. History or presence of impaired renal function as indicated by clinically significant abnormal creatinine, blood urea nitrogen (BUN), or urinary constituents (e.g., albuminuria) or moderate to severe renal dysfunction as defined by the Cockcroft Gault equation < 30 mL/min.
9. History or close family history (parents or siblings) of skin cancer or melanoma, or patient history of ocular-cutaneous albinism.
10. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions, determined as part of a screening comprehensive skin evaluation performed by a qualified dermatologist. Any concerning lesions identified during the screening period will be biopsied and results known to be benign prior to enrollment. If the pre- treatment biopsy results are of concern, the patient may need to be excluded from the study.
11. Volunteer is, in the opinion of the Study Investigator, not suitable to participate in the study.
12. Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing.
13. Significant hypersensitivity to study drug.
14. Inability to comply with QD injection regimen.
15. Patients who have been placed in

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation

Intervention(s)

Product Name: setmelanotide (preserved formulation)
Product Code: RM-493
Pharmaceutical Form: Solution for injection
INN or Proposed INN: setmelanotide
CAS Number: 920014-72-8
Other descriptive name: RM-493
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10.0-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use

Primary Outcome(s)

Primary end point(s): The primary endpoint is the mean percent change from baseline in body weight at the end of ~1 year of treatment.

Main Objective: To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in patients with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the end of 1 year of treatment.

Secondary Objective: To assess the effect of setmelanotide, over one year, on:
• Safety and tolerability of setmelanotide (including blood pressure [BP] and heart rate [HR]).
• Hunger.
• Percent change in body fat mass.
• Glucose parameters: fasting glucose, glycated hemoglobin (HbA1c), oral glucose tolerate test (OGTT) with focus on parameters of insulin sensitivity.
• Waist circumference.
• During withdrawal from drug: reversal of weight and hunger reduction during the double-blind placebo- controlled withdrawal period.

Timepoint(s) of evaluation of this end point: End of 1 year treatment

Secondary Outcome(s)

Secondary end point(s): Supporting secondary, tertiary and exploratory endpoints will include:
The safety and tolerability of setmelanotide QD SC injection will be assessed by the frequency and severity of adverse events (AEs) as well as changes in physical examinations, electrocardiograms (ECGs), vital signs (including resting BP and HR), laboratory evaluations, and injection site reactions.

Potential improvements in lipids (fasting cholesterol and triglycerides) as well as glucose parameters as measured by fasting glucose, HbA1c and OGTT with focus on parameters of insulin sensitivity will be assessed over time.

Several questionnaires will be utilized throughout the study to assess quality of life (IWQOL-Lite and PedsQL) along with the SF-36 health survey. As required by Food and Drug Administration (FDA) for central nervous system (CNS)-active obesity medications, changes in depression/suicidality as assessed by the C- SSRS and PHQ-9 will be monitored over the entire course of the trial.

Timepoint(s) of evaluation of this end point: Throughout the course of the study and end of approximately 1 year of treatment

Secondary ID(s)

RM-493-015

2017-002005-36-DE

Source(s) of Monetary Support

Rhythm Pharmacueticals, Inc

Ethics review

Status: Approved
Approval date: 21/12/2017
Contact: